About
Our Science
News
Contact Us
About
Our Science
News
Contact Us
Press Release
MEDIA COVERAGE
Press Releases
Articles
PRESENTATIONS
Events
View All
Press Release
Aug 27, 2024 |
ProJenX Announces Formation of Clinical Advisory Board
Read More
Press Release
Jun 20, 2024 |
ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Read More
Press Release
Mar 28, 2024 |
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
Read More
Press Release
Feb 14, 2024 |
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 29, 2023 |
ProJenX Receives Health Canada Clinical Trial Application Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 2, 2023 |
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Read More
Press Release
Mar 30, 2023 |
ProJenX Announces Formation of Scientific Advisory Board
Read More
Press Release
May 18, 2022 | ProJenX
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Read More
Press Release
Mar 1, 2022 | ProJenX
ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin
Read More
Press Release
Feb 16, 2022 | ProJenX
ProJenX Launches to Advance Novel, Targeted Therapies for ALS and Other Brain Diseases
Read More
Contact Us to Learn More About Our Fight Against ALS
Contact Us
